US2010247614A1PendingUtilityA1

Hemostatic wound dressing

49
Assignee: UNIV WASHINGTONPriority: Nov 19, 2007Filed: May 14, 2010Published: Sep 30, 2010
Est. expiryNov 19, 2027(~1.3 yrs left)· nominal 20-yr term from priority
Inventors:Shaoyi JiangHong XueGang Cheng
A61P 31/00A61P 31/04A61P 31/10C08F 20/36A61P 17/02C08F 120/36A61Q 19/00A61K 8/368A61K 2800/5426C08F 20/38A61K 8/8158C08F 120/38C08F 20/54C08F 220/36
49
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Hemostatic wound dressings that include cationic polymers and related hydrogels, methods for making and using the wound dressings.

Claims

exact text as granted — not AI-modified
1 . A wound dressing, comprising a cationic polymer comprising:
 (a) polymer backbone;   (b) a plurality of cationic centers, each cationic center covalently coupled to the polymer backbone by a first linker;   (c) a counter ion associated with each cationic center; and   (d) a hydrolyzable group covalently coupled to each cationic center through a second linker, wherein the hydrolyzable group is hydrolyzable to an anionic center to provide a zwitterionic polymer having the anionic center covalently coupled to the cationic center through the second linker.   
     
     
         2 . The wound dressing of  claim 1 , wherein the polymer has the formula:
   PB-(L 1 -N + (R a )(R b )-L 2 -A(=O)—OR c ) n (X − ) n      wherein   PB is the polymer backbone having n pendant groups L 1 -N + (R a )(R b )-L 2 -A(=O)—OR c );   N +  is the cationic center;   R a  and R b  are independently selected from hydrogen, alkyl, and aryl;   A(=O)—OR c  is the hydrolyzable group, wherein A is selected from the group consisting of C, S, SO, P, or PO, and R c  is an alkyl, aryl, acyl, or silyl group that may be further substituted with one or more substituents;   L 1  is a linker that covalently couples the cationic center to the polymer backbone;   L 2  is a linker that covalently couples the cationic center to the hydrolyzable group;   X −  is the counter ion associated with the cationic center; and   n is an integer from about 10 to about 10,000.   
     
     
         3 . The wound dressing of  claim 1 , wherein the counter ion is a hydrophobic organic counter ion. 
     
     
         4 . The wound dressing of  claim 1 , wherein the counter ion is selected from the group consisting of C1-C20 carboxylates and C1-C20 alkylsulfonates. 
     
     
         5 . The wound dressing of  claim 1 , wherein the counter ion is a therapeutic agent. 
     
     
         6 . The wound dressing of  claim 1 , wherein the counter ion is selected from the group consisting of an antimicrobial, an antibacterial, and an antifungal agent. 
     
     
         7 . The wound dressing of  claim 1 , wherein the counter ion is selected from the group consisting of amino acids, proteins, and peptides. 
     
     
         8 . The wound dressing of  claim 1 , wherein the hydrolyzable group releases a hydrophobic organic group on hydrolysis. 
     
     
         9 . The wound dressing of  claim 1 , wherein the hydrolyzable group releases a C1-C20 carboxylate on hydrolysis. 
     
     
         10 . The wound dressing of  claim 1 , wherein the hydrolyzable group releases a therapeutic agent on hydrolysis. 
     
     
         11 . The wound dressing of  claim 1 , wherein the hydrolyzable group releases an antimicrobial, an antibacterial, or an antifungal agent on hydrolysis. 
     
     
         12 . The wound dressing of  claim 1 , wherein the cationic center is selected from the group consisting of ammonium, imidazolium, triazaolium, pyridinium, morpholinium, oxazolidinium, pyrazinium, pyridazinium, pyrimidinium, piperazinium, and pyrrolidinium. 
     
     
         13 . The wound dressing of  claim 2 , wherein R a  and R b  are independently selected from the group consisting of C1-C10 straight chain and branched alkyl groups. 
     
     
         14 . The wound dressing of  claim 2 , wherein L 1  is selected from the group consisting of —C(═O)O—(CH 2 ) n — and —C(═O)NH—(CH 2 ) n —, wherein n is an integer from 1 to 20. 
     
     
         15 . The wound dressing of  claim 2 , wherein L 2  is —(CH 2 ) n —, where n is an integer from 1 to 20. 
     
     
         16 . The wound dressing of  claim 2 , wherein A is selected from the group consisting of C, SO, and PO. 
     
     
         17 . The wound dressing of  claim 2 , wherein R c  is C1-C20 alkyl. 
     
     
         18 . The wound dressing of  claim 2 , wherein R c  is an amino acid. 
     
     
         19 . The wound dressing of  claim 2 , wherein X −  is selected from the group consisting of halide, carboxylate, alkylsulfonate, sulfate; nitrate, perchlorate, tetrafluoroborate, hexafluorophosphate, trifluoromethylsulfonate, bis(trifluoromethylsulfonyl)amide, lactate, and salicylate. 
     
     
         20 . The wound dressing of  claim 1 , wherein the cationic polymer is a hydrogel. 
     
     
         21 . The wound dressing of  claim 20 , wherein the hydrogel is a chemical hydrogel. 
     
     
         22 . The wound dressing of  claim 20 , wherein the hydrogel is an interpenetrating network hydrogel. 
     
     
         23 . The wound dressing of  claim 20 , wherein the hydrogel comprises first and second polymers, wherein the first polymer is a cationic polymer hydrolyzable to provide a zwitterionic polymer, and wherein the second polymer is a zwitterionic polymer. 
     
     
         24 . The wound dressing of  claim 23 , wherein the first and second polymers are crosslinked. 
     
     
         25 . The wound dressing of  claim 23 , wherein the hydrogel is prepared by copolymerizing a first cationic monomer having a hydrolyzable group and second zwitterionic monomer. 
     
     
         26 . The wound dressing of  claim 24 , wherein the hydrogel is prepared by copolymerizing a first cationic monomer having a hydrolyzable group and second zwitterionic monomer. 
     
     
         27 . The wound dressing of  claim 25 , wherein the hydrogel is prepared by polymerizing the first monomer to provide a cationic polymer having hydrolyzable groups, adding the second monomer to the cationic polymer, and polymerizing the second monomer in the presence of the cationic polymer. 
     
     
         28 . The wound dressing of  claim 25 , wherein the hydrogel is prepared by polymerizing the second monomer to provide a zwitterionic polymer, adding the first monomer having a hydrolyzable group to the zwitterionic polymer, and polymerizing the first monomer in the presence of the zwitterionic polymer. 
     
     
         29 . The wound dressing of  claim 20 , wherein the hydrogel is prepared by polymerizing a first cationic monomer having a hydrolyzable group to provide a cationic polymer having hydrolyzable groups, and hydrolyzing at least a portion of the hydrolyzable groups of the cationic polymer. 
     
     
         30 . A method for treating a wound, comprising applying the wound dressing of  claim 1  to a wound.

Join the waitlist — get patent alerts

Track US2010247614A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.